Antineoplastons - Burzynski Therapy
|Burzynski Research Institute
Stanislaw R. Burzynski, MD, PhD
9432 Old Katy Rd, Suite 200
Dr. Burzynski discovered peptides and amino acid derivatives in the human body that control cancer, not by destroying cancer cells but by correcting them. He named these substances antineoplastons.
Antineoplastons are nontoxic substances that have shown to be a promising therapy for difficult-to-treat brain cancers, low- and intermediate-grade non-Hodgkin's lymphoma, and many common types of solid tumors. Note: Antineoplastons have not been approved by the Food and Drug Administration as safe and effective for the treatment of any disease or condition. However, clinical trials are under way on this treatment.
Dr. Burzynski has been approved by the Food and Drug Administration as Principal Investigator in over 70 clinical trial studies. These studies encompass a wide range of cancer types in both children and adults. However, he is best known for treating brain cancer.
After 25 years of experimentation, the outlook for antineoplastons in the treatment of cancer has never been brighter. However, Dr. Burzynski advises that the treatment is still considered experimental, and that no promises of effectiveness can be made.
All residents of the United States must participate and be treated under a current FDA-approved clinical trial or Special Exception. Residents of most other countries must receive FDA permission to ship antineoplastons to that country. All patients are treated on an outpatient basis. The treatment is self-administered and normally free of serious side effects.
Currently there is legislation underway to allow for choice of therapy in treating ones cancer that resulted from Thomas Navarro being denied treatment at Burzynski's clinic.
Mechanism of Action
Dr. Burzynski sees cancer as a disease of cellular information processing. Antineoplastons seem to correct the program inside the cell and can change a cancerous cell back to a normal cell. Dr. Burzynski described a study carried out at the Department of Pathology for the Department of Defense in Bethesda, Maryland. The study showed that using antineoplaston AS2-1 in tissue culture caused cancer cells to change back into normal cells after approximately two to three days. (1)
Healthy cells specialize as they develop. After a specific number of cellular divisions, these specialized cells are programmed to die. Cancer cells, due to incorrect programming, undergo uncontrolled cellular proliferation. They keep multiplying without limit until they finally kill the patient. Dr. Burzynski has postulated that antineoplastons reprogram cancer cells so they behave like normal cells, with a limited life span.
The antineoplastons have to be administered continually and for a long enough time to allow the previously cancerous cells to go through their life cycle to cellular death. If the therapy is slowed down or stopped too soon, the cell (which still has an incorrect program) will start behaving like a cancerous cell again.
Since antineoplastons occur normally in humans but are present in low levels in cancer patients, Dr. Burzynski believes that testing the level of antineoplastons can be used to diagnose cancer in the future.
Viewed 172208 times
All #56153's Answers